Parallax Volatility Advisers
DRNA

Parallax Volatility Advisers’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Parallax Volatility Advisers’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-45,300
Closed -$998K – 3821
2020
Q4 		$998K Sell
45,300
-81,300
-64% -$1.79M ﹤0.01% 2177
2020
Q3 		$2.28M Buy
+126,600
New +$2.62M ﹤0.01% 1633

Other funds holding DRNA

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Parallax Volatility Advisers's DRNA Position: Q1 2021 in Review

Parallax Volatility Advisers sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q1 2021, closing a stake of 56 shares — an estimated $1K sold.

Parallax Volatility Advisers first reported a position in DRNA in Q1 2018 and held it in 3 quarters. The position peaked at $331K in Q3 2020. 183 funds tracked by Wall St. Rank hold DRNA as of Q1 2021.

  • Parallax Volatility Advisers reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
  • Parallax Volatility Advisers sold 56 Dicerna Pharmaceuticals, Inc. shares in Q1 2021, an estimated $1K.
  • Parallax Volatility Advisers first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2018 and held it in 3 quarters.
  • Parallax Volatility Advisers's Dicerna Pharmaceuticals, Inc. position peaked at $331K in Q3 2020.
  • 183 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q1 2021.

Based on Parallax Volatility Advisers's 13F filing for Q1 2021, filed 14 May 2021.